after yesterdays agm statement the share price has risen 50% how much upside is left or is this another false dawn?
http://www.alexa.com/data/details/traffic_details/thewellnessshop.co.uk
womans hour link below.
http://www.bbc.co.uk/radio4/womanshour/04/2008_08_mon.shtml

A nice big end of day buy 2m + just under 30k is there News tomorrow !

looks good
Your email has been passed to me for a response as I have led on implementation of Beating the Blues in North Somerset.



We have recently implemented Beating the Blues self help e based Cognitive Behaviour Therapy programme in 5 access points across North Somerset in accordance with NICE guidelines We have implemented Beating the Blues at the same time as Books on Prescription for Mental Health and a pilot scheme to introduce an Advice and Guidance worker into a GP practice in Weston-super-Mare to access education, training, employment and social inclusion services.



The access points are The Campus Library, Worle, The For All Healthy Living Centre Library, Weston-super-Mare, FRIEND Resource Centre, Weston-super-Mare, Weston College Library and Clevedon Library.



The 5 licences expire December 2008 and at that point we will have to evaluate the programme locally and decide whether to continue the service as part of the proposed new Primary Care Mental Health Service which will be in place by the end of this year in North Somerset.



To date 17 people have registered to use Beating the Blues in North Somerset but it is to early to reach any conclusions as to effectiveness etc.



I hope the above meets your requirements but please contact me if I can be of any further assistance.



Hilary

nice buy at the end of day 11/03/2008...

Time Price Volume Value Buy/Sell Type(key)
16:30 1.48p 2,012,618 29,787 Buy OK

should be a blue day tomorrow i fill their could be some new out ......then well see 02p......enenjoy the ride it took some time but for tose of us that belived in this share there no surprize ............hope your all still here at 05p+

News flow most Important my view down to about 1.34 unless major news.

Update on PCT etc will be mid May thats how they work.
Dont bank on a party the whole Health system is like local authoritity / quango's / government system usally 1 -2 to month delay in hand shake.

2 further late buys last night recorded this morning at 1m each 1.43 and 1.42.

Flurry of buys this morning looking good.

has long been one of my un-faves, albeit that i made money on it a couple of years back (i think) .... so well done those who bought within the last month or two .... sp certainly rocketing away into at least recent new high ground

Heading for buys at 1.55

elbow- good! after having been in and out a few times quite profitably, my last purchase of these were at 1.54 which until now was not so smart-kept shares as when you deal with NICE/NHS and PCT's you know it will be protracted but always had faith in ULT

It all depends on News flow and as the quarterly News letter is well over due there must be something coming soon. The previous News letter was delayed due to deals been done which may be the case here. Seems to have stalled at 1.53p however. Sorry 1.51p profit taking possible now.

This has long dragged my rather small portfolio through the mud along with PXC & GTL. At this rate I will only have to worry about the other two lol (which I will ditch when I get time). As long as EO. , GOO hold up and this keeps moving up I'll still be smiling!

still think we will see a drop due to profit taking.

Well it looks like its got resonable support at 1.48 to 1.50p.
Just had a look at one of the other sites apparently there is an article in Nurse Practice magazine about the treatment of depression but not seen it yet. Anyone else ?

Nearly all buys (bar 1) since 2pm 2.56 million its close on ticking up again.
Thread on ADVFN suggests key MM is KBC who have been buying since 9.37 this morning.

most likely ramping a lot of it on that site

thanks cynic
nice of you to put your hands up and say that ..............now put your hands in your pocket and buy some .......................;-))

http://www.abc.net.au/health/thepulse/stories/2008/03/13/2188516.htm

chartists - is there a golden cross coming/ likely here? I have a 2 year chart with 50 and 200 dma looking like crossing soon...... or should I not read into the future too soon?

News letter out all postive

Yes sums up what we knew soild growth and income

mcmahons thanks copy in full below
Newsletter March 2008
This newsletter carries to a wider audience the information presented to our recent AGM and reflects on the development of the business over the last 3 years. In essence the message management conveyed to shareholders is that in the last 12 months Ultrasis has developed from being a pioneering provider of innovative health care to a mainstream provider within the UKs NHS. Our flagship cCBT programme, Beating the Blues, is now becoming more widely available through English primary care trusts. That is a sound platform on which to continue to build Ultrasis business model, providing innovative healthcare to both the public and private sectors in the UK and other markets.

Financial
In difficult markets Ultrasis is a growth story. In the year ended July 31st 2005 reported revenue was 907,000 and by the year ended July 31st 2007 this had grown to 1,577,000, a 74% increase. However, due to the nature of our business with the NHS, the bulk of our sales into the NHS are made in Q3 with licenses starting in Q4 so there is an imbalance between costs and income. We incur costs of account set up but gather very little revenue in the same financial year. Also, we adhere to an accounting practice that accounts for revenue as it is earned so a 12month contract is split, with 1/12th income being recognised each month. It is because of this that we felt it sensible this year to highlight our deferred revenue of 1,388,000 in the accounts. When this is taken into consideration and sales and cost of sales are brought into line, the substantial improvement in the Companys underlying performance over the last 2 years can be understood. Furthermore, once the notional charges required under FRS 20 regarding share options and capital expenditure on R&D are removed (both of which are accounted for as expenses in our statutory accounts) the underlying EBITDA performance is positive for the last 2 years.

Having reached a position of relative strength we have been able to invest more for the future and have marked employee remuneration to market, appointed a PR company and a new NOMAD and joint broker JM Finn; and expanded the customer service and account management teams.

Other key achievements over the 3 year period are the creation of a strong cash position (now being internally generated from operations rather than reliance on external funding), the conversion of the loan stock, removing a significant annual interest payment and cash liability which would have been due in 2008. The company is debt free. The board sees no reason why any further dilutive share issues will be required to support organic growth.

Share price (SP) / market cap
Share price is properly - beyond the companys control, but the boards policy is to build long term shareholder value. I spent some time at the AGM looking back over the past 3 years, highlighting the fact that there had been a number of spikes over that period predominantly surrounding announcements by NICE. Whilst the spikes were useful for some traders of our stock it would be hard to believe they represented a true valuation of the company at that time ie. +/- 30m market cap on 1m turnover. The SP did experience a period of stability around 2p for some 14 months mid 2006-mid 2007 but then with virtually no news flow, drifted to below 1p from there. The point I hope I got across to the meeting is that there was a period post the NICE announcement when both shareholders and PCTs expected Ultrasis to be handed a big cheque for a National implementation of BtB, an expectation that fuelled market speculation. But, with devolved procurement in the NHS, that never materialised.

Against the trend of the markets however, 2008 has seen sustained growth in SP to 1.2p on the back of some recent announcements and contract successes and with low volumes, the price seems to have stabilised.

A key point is that the SP in Jan 2005 was 0.3p and Ultrasis market cap was 2.86m. Since then there have been a number of share issues, mainly for CULS conversion and the Healthstar acquisition, but the share price has increased to 1.2p, giving a market cap of 17.7m - a six fold increase. Since the AGM the SP has moved forward to 1.43p giving a market cap of 21m. The real difference is that Ultrasis is now underpinned by substantive achievements, a strong positive cash flow and a sound platform from which to move forward from. Ultrasis is no longer a pure speculative play.

Comparison of 2005 with 2007 2005 2007
Renewal rates good Renewals highest ever
Single licence sales 10 licences or more the norm
Annual licences 2&3 year contract the norm
Highly dependent on one off contracts Broad and expanding customer base
Negative balance sheet Positive balance sheet
Large debt burden Debt free
Cash tight and outside funding required Cash in the bank - organic growth internally funded
Retail right owned by 3rd party Rights to all products owned by Ultrasis
Doing the best with what we have Professional image, strengthened teams, motivated staff

National Framework Agreement NHS/PASA
Having been told quite clearly by the Department of Health that no national purchase would take place (although the contract terms agreed still provide for one) we continued diligently to work at all levels (national directorate, SHAs, procurement hubs and PCTs) within the NHS to deliver BtB. We have also had continual dialogue with senior ministers in an effort to ensure they deliver on their policy and public commitments to provide BtB throughout the NHS.

Our discussions have resulted in numerous assurances from ministers:

CCBT is an important component in the delivery of psychological interventions.
We expect all PCTs to be able to offer NICE approved products.
We communicated with GPs and PCT Chief Executives and reminded them of the mandatory nature of NICE technical appraisals.
Advised PCTs of local funding flexibility from capital budgets.
By 2010/11 the NHS will spend 170m pa on the IAPT programme under the (CSR) Comprehensive spending review.
The Rt. Hon. Alan Johnson MP, Secretary of State for Health, then qualified his commitment, explaining that although CCBT is mandated by NICE, it is ultimately the responsibility of PCTs to ensure it is delivered and that SHAs are responsible for performance managing PCTs to ensure delivery of services the Pontius Pilate approach. He further stated that individual patients who are dissatisfied with the non availability of treatments to which they are entitled should consider using the established NHS complaints procedure.

Not all doom and gloom I hasten to add (see the following), just frustrating that public ministerial support and comment is not followed up with the necessary actions on the ground to deliver on these promises in a timely fashion. Too many patients remain untreated and suffer unnecessarily.

CSR / PSA (Public Service Agreement)
PSAs set out the key priority outcomes the Government seeks to achieve in the next spending period. It sets out the national performance indicators that will be used to measure progress towards the PSA.

PSA delivery agreement 18 lays out the relevant measure as The proportion of people who have depression/ or anxiety disorders who are offered psychological therapies based on a count of the number of individual patients who commence a course of evidence based psychological therapy.

This is how the 170m funding recently announced by Alan Johnston is going to be directed and we expect to participate fully in delivering the only NICE approved evidence based computer delivered therapy for mild to moderate depression and anxiety.

NHS achievements
Whilst we continue to broaden our customer base, the NHS will always be a significant part of Ultrasis business and in spite of the lack of a coherent approach toward policy implementation from the top, we continue to have success at both individual PCT level (not all PCTs will come together in a SHA procurement) and at SHA level where we have already won 3 key SHA contracts over the next 2 years, with a minimum total value of 1.37m. We will, of course, continue to build on these as well as secure others that have not yet complied with guidance.

In addition the contract with the DWPs Conditions Management Programme in the North West is showing considerable success. This is where we provide BtB delivered in partnership with Turning Point and Job Centres in the back to work programme. This has now grown in value, exceeding 100k pa.

Other Opportunities
We continue to broaden our customer base and exploit potential opportunities for the future as we have a product suite with outcomes that can potentially benefit a much wider population than that serviced by the NHS. We are continuing to push ahead to find a partner with whom to develop the US market and we now receive a number of enquiries from the EU where we continue to explore options for BtB in other languages.

YourCity.MD was launched towards the end of 2007 across 300 cities in the US, providing a local health site portal for patients and physicians to come together for information, advice, communication and feedback. Ultrasis has partnered with YourCity.MD and secured an exclusive position under the self care tab on their web site to promote the wellness shop.

The recent link up with six universities, utilising both the relief series product suite and BtB programme, shows yet again our value proposition in terms of efficacy and relevance to other markets. The university population has its own unique blend of stresses and incidence of depression and we believe that an online approach to addressing emotional and psychological needs will resonate well with this population.

Advisory Board
We were delighted to be able to announce the appointment of this board with such eminent members Sir Christopher Kelly KCB, a former Permanent Secretary of the Department of Health, Lord Victor Adebowale, CEO of Turning Point the UKs leading social care organisation and Professor Sir David Goldberg, formerly Professor of Psychiatry at the Institute of Psychiatry and long term advisor to the Department of Health. The appointment of this board marks Ultrasis transition from technology pioneer to established provider of essential mental health services to the public.

Non executive director: Tony Knight
We have appointed Mr Knight to our board and I was pleased to welcome him at the AGM.

Tony has over 30 years experience in the pharmaceutical industry and has held senior positions covering all business functions. Tony was the former Non Executive Chairman of Meldex International PLC and will bring considerable knowledge and experience to our board as well as supporting our corporate governance objectives and compliance.

NICE
The NICE Guideline for Treatment of Depression (last published in December 2004) is being updated and the Health Technology Assessment for CCBT (depression only) will be updated as part of this process. Until publication, Beating the Blues remains the only recommended treatment for depression.

There is a defined process for submission of supporting data by manufacturers and comment on the guidelines. At this point in time the initial scope for the guideline has not yet been published.

Ultrasis continues to collect evidence regarding the clinical efficacy and cost effectiveness of Beating the Blues which will further support and broaden the use of the product in primary and secondary care. Our published evidence base is second to none and further important papers will be published over the next six months.

Ultrasis welcomes the new guidelines as it provides further opportunity for NICE to Incorporate our latest research (about for instance, the effectiveness of Beating the Blues in secondary care environments and in co-morbid conditions). This will ensure that the use of Beating the Blues is allotted its proper prominent place in the treatment of depression and will provide further expanded direction to Primary care trusts (PCTs), psychologists, mental health commissioners and GPs.

Nigel Brabbins
Chief Executive
13th March 2008

--------------------------------------------------------------------------------